Recent Updates
Recently added Catalysts

Ha44

Phase 2

Head Lice Infestation | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Apr 28, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment38
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01907490Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice InfestationPHASE2 COMPLETED 38Mar 1, 2013Dec 1, 2013Apr 28, 2020 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of the Subjects With AEs.
3 months

Safety and tolerability assessed by AEs. Number of subjects with reporting AEs.

Secondary Endpoints
Pk Parameters: Cmax
0 to 8 hours
PK Parameters: Tmax
0-8 hours
PK Parameters: AUC(0-8)
0-8 hours
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALHa44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
Interventions
NameTypeDescription
Ha44 GelDRUGEligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
Unlock Study Design Details
Eligibility Criteria
Age Range6 Months — 17 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: 1. Male or female 2. 6 months to 17 years of age 3. Be in good health, as determined by medical history and physical examination 4. Has an active head lice infestation at screening as determined by an experienced evaluator. An active infestation is defined as the presence of at ...

Unlock Eligibility Criteria